News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

Press releases

2022

19 May, 2022 Egetis Therapeutics raises approximately SEK 180 million through an oversubscribed rights issue News Corporate Action Shares Issuance English Regulatory MAR IR Optional
28 April, 2022 Egetis Therapeutics publishes prospectus relating to the Rights Issue News Corporate Action Prospectus English Regulatory Listing Regulation IR Optional
26 April, 2022 Interim report January-March 2022 News English Regulatory MAR Report Interim Q1 IR Optional
20 April, 2022 Egetis Therapeutics’ 2021 annual report published News English Regulatory VPML Report Annual IR Optional
13 April, 2022 Bulletin from extraordinary shareholders’ meeting in Egetis Therapeutics AB and publication of timetable relating to the rights issue News Corporate Information General meeting Report of the AGM English Regulatory Listing Regulation IR Optional
21 March, 2022 NOTICE OF EXTRAORDINARY GENERAL MEETING IN EGETIS THERAPEUTICS News Corporate Information General meeting Notice English Regulatory Listing Regulation IR Optional
21 March, 2022 Egetis Therapeutics resolves on a fully guaranteed preferential rights issue of approximately SEK 180 million News Corporate Action Shares Issuance English Regulatory MAR IR Optional
17 February, 2022 Significant progress towards Emcitate® marketing applications in the US and Europe in 2023 News English Regulatory MAR Report Interim Yearend IR Optional
18 January, 2022 Egetis concludes that demonstrating treatment effects on T3 levels in MCT8-deficiency could provide a basis for marketing approval for Emcitate® in the US News Corporate Information Other Corporate Information English Regulatory MAR IR Optional mfn-cus-emcitate

2021

13 December, 2021 Egetis intends to submit a marketing authorisation application for Emcitate® to the European Medicines Agency based on existing clinical data News Corporate Information Other Corporate Information English Regulatory MAR IR Optional mfn-cus-emcitate
5 November, 2021 Nomination Committee appointed for the 2022 Annual General Meeting in Egetis Therapeutics News Corporate Information Nomination Committee English Regulatory Listing Regulation IR Optional
4 November, 2021 Interim report January-September 2021 News English Regulatory MAR Report Interim Q3 IR Optional
19 August, 2021 Emcitate development program progressing according to plan News English Regulatory MAR VPML Report Interim Q2 IR Optional mfn-cus-aladote
24 May, 2021 Chairman of the board of directors in Egetis Therapeutics acquires shares News Corporate Information Other Corporate Information English Regulatory Listing Regulation IR Optional
17 May, 2021 CEO and senior executives in Egetis Therapeutics acquire shares News Corporate Information Other Corporate Information English Regulatory Listing Regulation IR Optional
29 April, 2021 Bulletin from Egetis Therapeutics’ Annual General Meeting 2021 News Corporate Information General meeting Report of the AGM English Regulatory Listing Regulation IR Optional
22 April, 2021 Patient recruitment in the pivotal study with Emcitate progressing according to plan News English Regulatory Listing Regulation Report Interim Q1 IR Optional
19 April, 2021 Egetis Therapeutics appoints Yilmaz Mahshid as new CFO News Corporate Information Staff change English Regulatory MAR IR Optional
30 March, 2021 Egetis Therapeutics 2020 annual report published News English Regulatory VPML Report Annual IR Optional
26 March, 2021 Mats Blom nominated as new board member at Egetis Therapeutics News Corporate Information Nomination Committee English Regulatory Listing Regulation IR Optional
26 March, 2021 Dr Thomas Lönngren nominated as new Chairman of the Board at Egetis Therapeutics News Corporate Information Nomination Committee English Regulatory MAR IR Optional
17 February, 2021 Egetis Therapeutics presents the fourth quarter and the year-end report 2020 News English Regulatory Listing Regulation Report Interim Yearend IR Optional
15 February, 2021 Egetis appoints Dr Kristina Sjöblom Nygren as new CMO News Corporate Information Staff change English Regulatory Listing Regulation IR Optional
20 January, 2021 Peder Walberg appointed as interim Chief Medical Officer News Corporate Information Staff change English Regulatory Listing Regulation IR Optional

2020

30 December, 2020 Change in the number of shares and votes in Egetis Therapeutics News Corporate Action Shares English Regulatory LHFI IR Optional

Calendar and upcoming reports

February 22, 2024
Year-end Report Q4 2023

March 5-6, 2024
Carnegie Nordic Healthcare Seminar

Show more events

Share

Twitter
LinkedIn

Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10

E-mail: info@egetis.com